双相障碍心境稳定剂与抗精神病药单药及联合治疗的真实世界有效性:全国性个体内研究纳入315046例患者
中位随访7.1年,26.5%患者发生精神科住院。锂盐、丙戊酸盐、拉莫三嗪、卡马西平单药及15种抗精神病药单药均与住院风险降低相关;锂盐联合卡马西平、佐替平、阿立哌唑或丙戊酸盐较锂盐单药进一步降低住院风险。
要点
- 锂盐单药与住院风险降低相关(aHR 0.67,95%CI 0.66-0.68)。
- 锂盐联合卡马西平、佐替平、阿立哌唑或丙戊酸盐较锂盐单药进一步降低住院风险。
- 15种抗精神病药单药(含阿立哌唑、佐替平)与住院风险降低相关。
核心结论
- 心境稳定剂和抗精神病药单药及联合治疗在预防精神科住院方面效果存在差异,可為双相障碍临床治疗决策提供参考。
研究设计与样本
- 基于日本全国医保索赔与特定健康检查数据库的 population-based 队列研究,采用个体内设计。
- 纳入2013年4月1日至2022年3月31日在精神科诊疗机构就诊、主要诊断为双相障碍且年龄≥20岁的患者,随访至2023年5月31日。
- 暴露包括心境稳定剂或抗精神病药单药治疗,以及锂盐联合另一种心境稳定剂或锂盐、丙戊酸盐或拉莫三嗪联合常用抗精神病药的联合治疗。
- 主要结局为至精神科住院的时间,采用分层Cox回归估计调整风险比(aHR)及95%置信区间。
主要发现
- 与未使用任何心境稳定剂相比,锂盐单药(aHR 0.67,95%CI 0.66-0.68)、丙戊酸盐(aHR 0.71,95%CI 0.70-0.73)、拉莫三嗪(aHR 0.72,95%CI 0.69-0.75)和卡马西平(aHR 0.74,95%CI 0.70-0.78)单药与住院风险降低相关。
- 与未使用任何抗精神病药相比,15种抗精神病药单药与住院风险降低相关,包括阿立哌唑(aHR 0.73,95%CI 0.70-0.75)和佐替平(aHR 0.74,95%CI 0.69-0.79)。
- 与锂盐单药相比,锂盐联合卡马西平(aHR 0.73,95%CI 0.64-0.83)、佐替平(aHR 0.82,95%CI 0.72-0.93)、阿立哌唑(aHR 0.87,95%CI 0.82-0.92)或丙戊酸盐(aHR 0.92,95%CI 0.87-0.97)与住院风险进一步降低相关。
临床怎么用
- 在双相障碍临床管理中,可参考本研究中与住院风险降低相关的单药及联合治疗方案进行个体化选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-world evidence on pharmacotherapy for bipolar disorder remains limited; in particular, the effectiveness of combination therapies that are widely used in clinical practice has not been systematically assessed. AIMS: To assess the effectiveness of mono- and combination therapy with mood stabilisers and antipsychotics in preventing psychiatric hospitalisation. METHOD: This population-based cohort study used a within-individual design and data from the National Database of Health Insurance Claims and Specific Health Check-ups of Japan. Patients aged ≥20 years, with a primary diagnosis of bipolar disorder treated in psychiatric settings between 1 April 2013 and 31 March 2022, were included. Follow-up continued until 31 May 2023. Exposures included monotherapy with mood stabilisers or antipsychotics, and combination therapy involving (a) lithium plus another mood stabiliser or (b) lithium, valproate or lamotrigine plus a commonly prescribed antipsychotic. The primary outcome was time to psychiatric hospitalisation. Adjusted hazard ratios (aHRs) with 95% confidence intervals were estimated using stratified Cox regression. RESULTS: Among 315 046 patients (median follow-up 7.1 years), 83 621 (26.5%) experienced psychiatric hospitalisation. Monotherapy with lithium (aHR 0.67 [0.66-0.68]), valproate (aHR 0.71, 95% CI 0.70-0.73), lamotrigine (aHR 0.72, 95% CI 0.69-0.75) and carbamazepine (aHR 0.74, 95% CI 0.70-0.78) was associated with reduced hospitalisation compared with non-use of any mood stabilisers. Antipsychotic monotherapy with 15 agents, including aripiprazole (aHR 0.73, 95% CI 0.70-0.75) and zotepine (aHR 0.74, 95% CI 0.69-0.79), was also associated with reduced risk compared with non-use of any antipsychotics. Combination therapy with lithium plus carbamazepine (aHR 0.73, 95% CI 0.64-0.83), zotepine (aHR 0.82, 95% CI 0.72-0.93), aripiprazole (aHR 0.87, 95% CI0.82-0.92) or valproate (aHR 0.92, 95% CI 0.87-0.97) was associated with further reductions in hospitalisation risk compared with lithium monotherapy. CONCLUSIONS: This large, population-based study showed that monotherapy and combination therapy with mood stabilisers and antipsychotics varied in their effectiveness in preventing psychiatric hospitalisation. These findings may inform treatment decisions in the clinical management of bipolar disorder.
引用
- Okumura Y, Tamune H, Harada H, et al. Real-world effectiveness of mono- and combination therapies of mood stabilisers and antipsychotics in bipolar disorder: nationwide, within-individual study of 315 046 patients. Br J Psychiatry. 2026. PMID: 42057566. doi:10.1192/bjp.2026.10636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。